

A SIMPLE AND POWERFUL TEST OF VACCINE WANING

GELLÉRT PERÉNYI¹, MATIAS JANVIN², MATS J. STENSRUD^{1,*}

¹*Institute of Mathematics, Ecole Polytechnique Fédérale de Lausanne, Switzerland ,*

²*Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics,
University of Oslo, Oslo, 0372, Norway*

ABSTRACT. Determining whether vaccine efficacy wanes is important for individual and public decision making. Yet, quantification of waning is a subtle task. The classical approaches cannot be interpreted as measures of declining efficacy unless we impose unreasonable assumptions. Recently, formal causal estimands designed to quantify vaccine waning have been proposed. These estimands can be bounded under weaker assumptions, but the bounds are often too wide to make claims about the presence of vaccine waning. We propose an alternative approach: a formal test to determine whether a treatment effect is constant over time. This test not only gives a considerable power gain compared to existing approaches but is also valid under plausible assumptions that are expected to hold in vaccine trials. We illustrate the increase in power through real and simulated examples, using three different approaches to compute the test statistics. Two of these approaches are based solely on summary data, accessible from existing clinical trials. Beyond our test, we also give new results that bound the waning effect. We use our methods to reanalyze data from a randomized controlled trial of the BNT162b2 COVID-19 vaccine. While prior analysis did not establish waning, our test rejects the null hypothesis of no waning.

Keywords: causal inference, challenge trial, hypothesis test, vaccine waning

* Corresponding author: mats.stensrud@epfl.ch.




FIGURE 1. Illustration of outcomes in a 2-arm randomized controlled trial over two intervals. Second interval observation is conditional on being event-free at time 1.

1. INTRODUCTION

Consider a randomized controlled trial (RCT) evaluating a vaccine against an infectious disease (e.g., HIV). Using data from the RCT, researchers estimated vaccine efficacy (VE) to be 0.8 one month after vaccination. To assess if the VE changed at later times, the participants who were event-free in the first analysis were included in a subsequent analysis at three months that gave a $\widehat{VE} = 0.6$, see Figure 1. The research group concluded that the efficacy had decreased at three months; that is, the vaccine effect had waned.

A key question is whether such a contrast of VEs at different times gives a meaningful notion of waning. To answer this question, we take for granted that the term waning alludes to a declining causal effect; that is, vaccine protection that decreases over time. To draw valid inference on a causal effect, the populations being compared under vaccination or no vaccination (e.g., placebo) should be exchangeable. Conceptually, this means that the distributions of risk factors for infection are expected to be similar in the two treatment groups (see for example, Hernan and Robins (2023)). Randomization ensures exchangeability for the comparison at the time of the first analysis (at one month). By the time of the subsequent analysis (at three months), however, conditioning on being event-free induces post-randomization selection: the participants who were event-free under vaccination differ from those who were event-free without vaccination. There is an additional problem when comparing VEs over time. Even within the same treatment arms, the analyses at the two subsequent intervals are estimated in different populations, making the declining VEs hard to interpret. See Figure 3 for the changing distribution of susceptibility over time and across treatment arms.

These concerns are not merely theoretical; heterogeneity in susceptibility is widespread. To fix ideas, we provide an extreme example. Consider a trial of a vaccine against CCR5-tropic HIV (Piccininni and Stensrud, 2025). Suppose that all individuals were in contact with the infectious agent, that is, they were naturally “challenged”, within the first month. The VE was estimated to be 0.8 after one month. Suppose further that the individual-level effect of the vaccine is constant in time: more precisely, had we challenged individuals with an infectious agent immediately after a one-month isolation period, we would have exactly the same outcome as if we had challenged the individuals immediately after a three-month isolation period. Then, the untreated participants who were not infected after the challenge must be inherently immune to the disease (to be concrete, they could be homozygous for the CCR5 $\Delta 32$ gene variant). Thus, by the

time of the second analysis, all unprotected trial participants, regardless of the arm, have already experienced the outcome, while those who are protected, either by the vaccine or their genetically induced immunity, will remain event-free at time 2, either by the lack of exposure or by their immunity. It follows that no new events will occur in either of the two arms, and the conventional VE estimate would be equal to 0. This estimate, however, contradicts the fact that the vaccine effect, on an individual-level, is time-invariant.

This extreme example illustrates a point: conventional VE estimates cannot be used to establish waning. Such analyses are subject to selection bias due to depletion of susceptibles, somewhat similar to issues with hazard ratios (see, e.g., Hernán (2010); Dumas and Stensrud (2025)). In practice, the magnitude of bias is unknown and can, in principle, be large, although likely not as extreme as in our illustrative example.

Recognizing the problems with the conventional waning analyses, Janvin et al. (2024) proposed an alternative estimand for VE, based on the idea of challenge trials. In particular, their estimand could be computed in a hypothetical target trial with controlled exposure of the participants (Bernstein et al., 2015; Schmoele-Thoma et al., 2022). However, such trials are rarely conducted, as exposing participants, regardless of their health status, to infectious pathogens is unethical (Hope and McMillan, 2004). With data from conventional RCTs, the estimand of interest is only partially identifiable, i.e., it is bounded under reasonable assumptions. Here, we introduce another approach to assess the existence of vaccine waning. Our work is grounded on a formal causal formulation of a declining treatment effect, related to Janvin et al. (2024). However, unlike Janvin et al. (2024), we formulate a sharp null hypothesis of no waning and propose a test that is powerful, simple, and assumption-lean. In particular, the test can be conducted under reasonable assumptions in conventional vaccine trials, either using individual-level or summary data. We furthermore suggest a strategy in Appendix D.1, based on some additional in-principle testable assumptions, to improve the bounds derived by Janvin et al. (2024).

2. OBSERVED DATA STRUCTURE

Consider i.i.d. data from an RCT in which individuals are assigned to treatment $A \in \{0, 1\}$ corresponding to placebo or vaccine. Define $Y_k \in \{0, 1\}$ as an indicator of the outcome occurring by the end of interval k . Thus, $\Delta Y_k := Y_k - Y_{k-1}$ is an indicator of whether the outcome has occurred in interval k . To simplify the presentation, we will treat these intervals as discrete. Yet, the test is valid in a continuous-time setting as well, with minor modifications. As the data are assumed to be i.i.d., the subscripts indicating individuals are omitted. The notation in Figure 1 stands for potential outcomes under different levels of treatment. For example, $\Delta Y_1^{a=0}$ is the outcome at time 1 under an intervention that sets the treatment to $a = 0$.

As highlighted in Section 1, the VE at time 2 is not a causal contrast. Consider instead a contrast among those who would survive the first interval, regardless of the treatment assignment,

$$E[\Delta Y_2^{a=1} | \Delta Y_1^{a=1} = \Delta Y_1^{a=0} = 0] \quad \text{vs} \\ E[\Delta Y_2^{a=0} | \Delta Y_1^{a=1} = \Delta Y_1^{a=0} = 0].$$

By restricting the analysis to those who survive under both treatment assignments, the two populations are comparable at time 2. This contrast is an example of principal stratum effects (PSEs) (Frangakis and Rubin, 2002).

However, we need to be careful when comparing effect contrasts among those who would survive under both levels of treatment at the second time to the same contrast among the general population at the first time: even if the analysis at each time has a causal interpretation, the two comparisons are computed in different populations. This complication concerning the PSE is particular to our setting and goes beyond the well-known critique of the PSE being a cross-world estimand (Robins, 1986; Richardson and Robins, 2013; Stensrud et al., 2023).

Consider instead an unconventional randomized 4-arm trial where participants are randomly assigned to one of the two levels of treatment and one of the two possible times of exposure (visualized in Figure 2):

Define exposure at time k as $E_k \in \{0, 1\}$ for $k \in \{1, 2\}$, corresponding to isolation ($E_k = 0$), or exposure through some controlled procedure ($E_k = 1$). We will not presume that we have data from this unconventional trial, but instead use this as a target trial, motivating our estimand.

In our derivations, we will use the following assumption from Stensrud and Smith (2023):

Assumption 1 (Exposure necessity).

$$E_k^a = 0 \implies \Delta Y_k^a; E_2^a = 0 \implies \Delta Y_2^a = 0,$$

for all $a \in \{0, 1\}, k \in \{1, 2\}$.

The intervention on exposure happens at two times in the 4-arm trial. The potential outcome at time 1 is defined under the intervention setting exposure to 1, and the potential outcome at time 2 is defined under an intervention setting exposure at time 1 to be 0 and exposure at time 2 to be 1. Thus, in this hypothetical trial, participants are exposed to the pathogen according to a controlled procedure at a specific time.

The potential outcome at time 2 is defined under an intervention that isolates individuals at time 1. Thus, those who were assigned to $e_1 = 0, e_2 = 1$ will not develop the outcome at the first time; they cannot be infected without exposure, following Assumption 1. The random assignment of treatment and exposure implies that the populations in all four arms are exchangeable, see Figure 3 for an illustration.

As proposed by Janvin et al. (2024), we define the challenge effects as follows:

Definition 1 (Marginal challenge effect).

$$(1) \quad VE_1^{\text{challenge}} = 1 - \frac{E[\Delta Y_1^{a=1, e_1=1}]}{E[\Delta Y_1^{a=0, e_1=1}]},$$

$$(2) \quad VE_2^{\text{challenge}} = 1 - \frac{E[\Delta Y_1^{a=1, e_1=0, e_2=1}]}{E[\Delta Y_1^{a=0, e_1=0, e_2=1}]}$$




FIGURE 2. 4-arm randomized controlled trial: Individuals are randomized to treatment and to the time of the exposure. Due to isolation, those who are assigned to time 2 exposure are exchangeable with those who are assigned to exposure at time 1. X denotes the distribution of the baseline characteristics in the trial population, which is, by randomization and Assumption 1, expected to be identical in all 4 arms.

The challenge effect conditional on baseline covariates is defined analogously, see Appendix H for details.

The challenge effect quantifies the effect of the vaccine in each interval in a way that is insensitive to the observed exposure pattern and the changing distribution of the unobserved heterogeneities over time. If $VE_1^{\text{challenge}}$ exceeds $VE_2^{\text{challenge}}$, then the protective effect of the vaccine has decreased over time, within the population that has been defined pre-randomization (Janvin et al., 2024).

While a “challenge trial”, such as the one illustrated in Figure 2, is sufficient to identify both $VE_1^{\text{challenge}}$ and $VE_2^{\text{challenge}}$, conducting such a trial is usually unethical, as deliberately exposing individuals to the pathogen could cause severe harm; hence, they are rarely conducted. Challenge trials can be run in healthy volunteers to minimize the risk of severe adverse effects; however, this approach typically fails to reflect the population of interest.

Janvin et al. (2024) derived conditions under which a waning parameter can be partially identified, even if the data are from a standard 2-arm RCT, in which exposure was neither intervened on nor measured, such as the one illustrated in Figure 1. Yet, the bounds derived for the second interval challenge effect can be wide, often including the first interval challenge effect, which prohibits a firm claim about the waning of the vaccine.

3. A FORMAL TEST

Consider the following sharp null hypothesis of no waning:

Hypothesis 1 (Sharp null hypothesis).

$$\Delta Y_1^{a,e_1=1} = \Delta Y_2^{a,e_1=0,e_2=1} \text{ w.p.1 } \forall a \in \{0, 1\}.$$

The sharp null hypothesis (1) states that anyone who would experience the outcome under exposure would do so regardless of whether exposure occurs at time 1 or at time 2. In short, individual susceptibility to exposure is constant across intervals and independent of exposure timing.




FIGURE 3. Illustration of two different trial designs. In conventional trials, the populations under treatment and no treatment are exchangeable at baseline. Without intervening on the exposure. Among exposed at time 1, the treated and the untreated groups are exchangeable as well, assuming treatment blinding, yielding an observed vaccine efficacy (VE) of 0.5 in this example. However, by time 2, the depletion of susceptibles (i.e., selective exclusion from the at-risk population of the doomed and harmed or doomed and helped strata, depending on the assigned treatment), alters the distribution of susceptibility of the at-risk population. Even without waning, the exposed at time 2 all belong to the same two susceptibility groups (principal strata), and the observed vaccine efficacy falls to 0. In contrast, in a challenge trial, the four arms are exchangeable at baseline. Isolation ensures participants assigned to exposure at time 2 remain at risk until then, making them exchangeable at the time of the exposure as well. Consequently, the challenge vaccine efficacy is 0.5 at both times, equal to the proportion in the doomed-or-harmed populations divided by the proportion in the doomed-or-helped populations in this hypothetical example.

We further restrict the exposure intervention to have no carry-over effect on the outcome. That is, exposure at time 1 cannot affect the outcome at time 2 except through survival. This restriction is compatible with a fixed incubation period of an infectious agent.

Assumption 2 (Exposure exclusion restriction).

$$\Delta Y_2^{a,e_1,\delta y_1=0,e_2=1} = \Delta Y_2^{a,\delta y_1=0,e_2=1} \quad \forall a, e_1 \in \{0, 1\}^2$$

Assumption 2 holds if all causal paths from E_1 to ΔY_2 are intersected by ΔY_1 or E_2 . However, it fails if exposure followed by survival at time 1 creates sustained immunity that prevents the development of the outcome at time 2.

Remark 1 (Null hypothesis under Assumption 2). Suppose that Assumptions 1 and 2 hold. An alternative formulation of the effect restriction using nested counterfactuals is

$$\Delta Y_2^{a,e_1,e_2=1} = \Delta Y_2^{a,e_1,\Delta Y_1^{a,e_1},e_2=1}.$$

By Assumption 1 $\Delta Y_1^{a,e_1=0} = 0$, thus

$$\begin{aligned} \Delta Y_2^{a,e_1=0,e_2=1} &= \Delta Y_2^{a,e_1=0,\Delta Y_1^{a,e_1=0},e_2=1} \\ &= \Delta Y_2^{a,e_1=0,\delta y_1=0,e_2=1} = \Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1}. \end{aligned}$$

Therefore, under Assumptions 1 and 2, Hypothesis 1 is equivalent to

$$\begin{aligned} \Delta Y_1^{a,e_1=1} &\stackrel{H_0}{=} \Delta Y_2^{a,e_1=0,e_2=1} \\ &= \Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1} = \Delta Y_2^{a,e_1=0,\delta y_1=0,e_2=1} \end{aligned}$$

Suppose Hypothesis 1 holds. Consider an individual who was exposed in the first interval but remained event-free. This individual will remain event-free at time 2 as well, regardless of the time 2 exposure. This observation is related to a constraint on the distribution of joint counterfactuals under Hypothesis 1, which we discuss in Appendix A.

Remark 2 (Population- vs individual-level waning). In principle, the challenge effects (Equations (1) and (2)) can be equal at times 1 and 2 even if $\Delta Y_1^{a,e_1=1} \neq \Delta Y_2^{a,e_1=0,e_2=1} w.p.$ 0. However, assume that

$$\Delta Y_1^{a=0,e_1=1} = \Delta Y_2^{a=0,e_1=0,e_2=1} w.p.1,$$

but not necessarily for $a = 1$. Conceptually, this assumption states that the risk of infection under placebo does not depend on the time of exposure. An argument supporting this assumption is that no active ingredient is administered in the placebo arm, and thus, the immune system's response to exposure should not depend on the time to first exposure. Then, the population-level notion of no vaccine waning is equivalent to the sharp null hypothesis, if there is no perfect cancellation in the following sense: exactly the same number of people experience "positive waning", that is, the improvement of the vaccine over time, as the number of people who experience "negative waning", that is, the deterioration of the vaccine over time. Such a perfect cancellation of positive and negative effects is unlikely. Thus, we can often intuitively treat the sharp null of no waning, and

population-level no waning ($VE_1^{\text{challenge}} = VE_2^{\text{challenge}}$) as equivalent. We provide a more formal argument building on the principal strata framework in Appendix A.

The next results will lead to a simple testing strategy of the null hypothesis. To describe this result, consider first another assumption that is plausible in a blinded trial:

Assumption 3 (No treatment effect on exposure in the unexposed).

$$E_1^{a=0} = E_1^{a=1} \quad \text{and} \quad E_2^{a=0, e_1=0} = E_2^{a=1, e_1=0}$$

Assumption 3 requires that there is no effect of treatment on time 1 exposure and on time 2 exposure following isolation. Conceptually, there is no causal path from A to E_1 . Furthermore, there is no causal path from A to E_2 except through E_1 or ΔY_1 . In a blinded trial, the exposure-seeking behavior at time 1 should not be a function of the actual treatment received. Yet, at time 2, those who developed the outcome at time 1, might reduce their contacts, for example, to minimize the spread of the disease. If the vaccine has an effect on the outcome at time 1, then the time 2 exposure might decrease at an increased rate among the placebo recipients. However, under isolation, the treatment would not affect their survival, by Assumption 1. Therefore, if the treatment is blinded, the time 2 exposure would be the same under both treatment and no treatment, making Assumption 3 plausible.

Assumption 3 is less restrictive than common assumptions in infectious disease epidemiology. In particular, random mixing is often assumed, which would require unconditional independence between the treatment and the exposures at both times, which implies Assumption 3. Moreover, under random mixing, the two exposures cannot be confounded; this is a restriction that Assumption 3 does not impose. Consider also the following exchangeability condition:

Assumption 4 (Exposure exchangeability).

$$\begin{aligned} E_1^a &\perp\!\!\!\perp \Delta Y_2^{a, e_1=0} | E_2^{a, e_1=0}, & E_1^a &\perp\!\!\!\perp \Delta Y_1^{a, e_1}, \\ E_2^{a, e_1=0} &\perp\!\!\!\perp \Delta Y_2^{a, e_1=0, e_2}. \end{aligned}$$

Exchangeabilities between the potential outcomes and the time 1 exposure are guaranteed by the lack of exposure-outcome confounders. However, in practice, exposure at time 1 and time 2 can be confounded by, for example, behavioral patterns. Thus, to make the independence between E_1^a and $\Delta Y_2^{a, e_1=0}$ plausible, we have to control for the time 2 exposure. Moreover, $E_2^{a, e_1=0} \perp\!\!\!\perp \Delta Y_2^{a, e_1=0, e_2=1}$ is equivalent to $E_2^{a, e_1=0} \perp\!\!\!\perp \Delta Y_2^{a, e_1=0, e_2=1} | \Delta Y_1^{a, e_1=0}$ under Assumption 1. Conceptually, this independence holds if there is no exposure-outcome confounding.

Under the directed acyclic graph (DAG) proposed by Janvin et al. (2024), Assumption 4 holds. See Appendix E for a replication of the DAG and a discussion on the Assumptions in Janvin et al. (2024).

The four assumptions introduced so far allow us to derive a simple equality that motivates our hypothesis test:

Proposition 1 (Invariant incidence rates). *Suppose that Assumptions 1-4 hold. Under Hypothesis 1*

$$IR_1 := \frac{E[\Delta Y_1 | A = 1]}{E[\Delta Y_1 | A = 0]} = \frac{E[\Delta Y_2 | A = 1]}{E[\Delta Y_2 | A = 0]} := IR_2.$$

See Proof in Appendix B.

Thus, Proposition 1 allows us to test Hypothesis 1 by comparing incidence ratios (IR_1 , IR_2).

We emphasize that incidence ratios are not hazard ratios, because time-varying hazard ratios (HRs) are often used in the literature when studying the waning of a vaccine. In a discrete-time setting, the observed hazard ratios are

$$HR_1 := \frac{E[\Delta Y_1 | A = 1]}{E[\Delta Y_1 | A = 0]} \quad HR_2 := \frac{E[\Delta Y_2 | \Delta Y_1 = 0, A = 1]}{E[\Delta Y_2 | \Delta Y_1 = 0, A = 0]}.$$

At the first time, all individuals are event-free, regardless of which treatment arms they were randomized to. Thus, $IR_1 = HR_1$. By Proposition 1, under the null hypothesis $HR_1 = HR_2$, if and only if $P(\Delta Y_1 = 0 | A = 0) = P(\Delta Y_1 = 0 | A = 1)$, that is, the vaccine has no population-level effect on survival at the first time. Assuming that no effect of the vaccine is observed at the beginning of the study is unrealistic. Therefore, a change in the HR over time, unlike a change in the IR over time, is not a measure of waning. We quantify the bias of studying HRs instead of IRs in Appendix F, and illustrate the performance of the hazard ratio-based testing in Appendix C.

The test itself is suitable for assessing the presence of waning, however, it is generally uninformative of the magnitude of waning. In Appendix D, we discuss the interpretation of the ratio of the incidence ratios when the alternative of the null hypothesis holds, and possible improvements on the bounds of Janvin et al. (2024) when waning is present.

4. ESTIMATION AND DATA ANALYSIS

The test can be implemented, using summary data only, see Appendix G for details. Thus, most published vaccine trials can be reanalyzed, given that they have the incidence recorded at least at two times. First, we revisit the BNT162b2 trial analyzed by Janvin et al. (2024) and show that our test is able to detect waning in the same setting in which they could not claim waning previously. Then we give an example where the test does not reject the null hypothesis, and argue that the test result agrees with biological explanations, illustrated by a *Helicobacter pylori* vaccine study.

Janvin et al. (2024) have analyzed a blinded RCT, published by Thomas et al. (2021), in which trial participants were randomized to receive a placebo ($A = 0$) or the BNT162b2 COVID-19 vaccine ($A = 1$). We are following the same division of the follow-up to the first and second interval as Janvin et al. (2024) in their main analysis, and an identical estimation procedure of the conditional expectation $E[Y_k | A = a]$ for $a \in \{0, 1\}$, $k \in \{1, 2\}$, where Y_k is the cumulative incidence by the end of interval k . Since their assumptions only allowed partial identification of $VE_2^{\text{challenge}}$, they compared the point-identified $\widehat{VE}_1^{\text{challenge}}$ to the estimated lower and upper bounds of the second interval challenge effects. $\widehat{\mathcal{L}}, \widehat{\mathcal{U}}$, respectively. Although their point estimates suggested a waning effect of the vaccine, the null hypothesis of no waning could not have been rejected.

In comparison, the point estimate of $\widehat{IR}_1/\widehat{IR}_2$ is 0.48 ($P = 0.01$, 95%*CI* [0.443, 0.52]), thus clearly rejecting our null hypothesis of no change in the potential outcome of an individual upon exposure over time, at the 5% level. Unless the condition in Remark 2 holds, i.e., that the number of people for whom the vaccine's effect improves over time equals the number for whom its efficacy decreases, the rejection can be interpreted as evidence of a change in the population challenge effect over time, i.e., waning vaccine efficacy.

Consider now a second example. Zeng et al. (2015) performed a double-blind, placebo-controlled RCT, to assess the efficacy, safety and immunogenicity of the of *Helicobacter pylori* vaccine among children in China. The trial participants were randomized 1:1 to the two arms and 99% of them completed the three-dose vaccination schedule. The primary analysis was performed among these participants (per-protocol-analysis) to assess the *H. pylori* infection in the first 12 months, following the completion of the vaccine schedule.

Incidence data has been published at months 4,8,12,24, and 36. To compare with the primary analysis, we compared the incidence ratio until month 8 (IR_1), to the incidence ratio between month 8 and month 12 (IR_2). In the first period, there were 36 and 10 events for 1416 and 1403.6 person-years at risk in the placebo and treatment arms, respectively. Following that, in the second period, there were 14 and 4 events for 673.6 and 670.7 person-years at risk in the placebo and treatment arms, respectively. Using the direct δ -method, we derive the estimate for $\widehat{IR}_1/\widehat{IR}_2 = 0.977$ ($P = 0.97$ 95%*CI* [0.263, 3.63]).

The test statistic agrees with the findings of Zeng et al. (2015); they have found that VE is 72% (95%*CI* [42.4%, 87.6%]) at month 8 and 71.8% (95%*CI* [48.2%, 85.6%]) at month 12. Even though we argued that the naive VE should not be used for assessing vaccine waning due to the selection-bias introduced, their analysis of the incidence also points towards no waning.

In practice, arguments about waning are often based on the the decay of immunological responses, measured by for example antibody levels. Zeng et al. (2015) measured the serum-specific antibodies in the vaccine and the placebo group. While at baseline the concentration were similar in the two treatment group, the vaccination elicited strong immune response. The concentration of the serum-specific antibodies did not decrease significantly over time, agreeing with our test results.

5. DISCUSSION

The challenge effect is a suitable estimand to measure the changes in the protective effect of the vaccine. However, it is not possible to point identify the challenge effect from conventional RCTs, and the sharp bounds of partial identification can often be prohibitively wide to make claims about the waning of the vaccine.

We show that instead of identifying the challenge effect, a sharp null hypothesis of no waning can be assessed accurately, with minimal assumptions; that is, unless some unrealistic cancellations of waning hold, we can interpret the null hypothesis as equivalent to the population level notion of no waning, $VE_1^{\text{challenge}} \neq VE_2^{\text{challenge}}$. We derive a simple test statistic for the null hypothesis, which can be computed using the observed data from a standard RCT. Even when there is no access to patient-level data, the test statistics

can be computed using summary data only. The quantities involved are interpretable and observable, making the test accessible to a wider audience.

The test is designed to assess the equality of the parameters, that is, the statistically significant existence of waning. When waning is confirmed by the test, further steps can be taken to try to determine the magnitude of waning. This could, e.g., be a follow-up trial, a reanalysis of the existing data with methods building on the results from Janvin et al. (2024), or additional analyses leveraging expert knowledge on exposure probabilities, as discussed in Appendix D.1.

REFERENCES

- Miguel A. Hernan and James M. Robins. *Causal Inference: What If*. CRC Press, December 2023. ISBN 978-1-4200-7616-5.
- Marco Piccininni and Mats J Stensrud. Immune-selection stability is a neglected property of the causal risk ratio. *American Journal of Epidemiology*, page kwaf086, April 2025. ISSN 0002-9262. doi: 10.1093/aje/kwaf086.
- Miguel A. Hernán. The Hazards of Hazard Ratios. *Epidemiology (Cambridge, Mass.)*, 21(1):13–15, January 2010. ISSN 1044-3983. doi: 10.1097/EDE.0b013e3181clea43. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653612/>.
- Elise Dumas and Mats J. Stensrud. How hazard ratios can mislead and why it matters in practice. *European Journal of Epidemiology*, 40(6):603–609, June 2025. ISSN 0393-2990, 1573-7284. doi: 10.1007/s10654-025-01250-9. URL <https://link.springer.com/10.1007/s10654-025-01250-9>.
- Matias Janvin, , and Mats J. Stensrud. Quantification of Vaccine Waning as a Challenge Effect. *Journal of the American Statistical Association*, 0(0):1–11, December 2024. ISSN 0162-1459. doi: 10.1080/01621459.2024.2408776.
- David I. Bernstein, Robert L. Atmar, G. Marshall Lyon, John J. Treanor, Wilbur H. Chen, Xi Jiang, Jan Vinjé, Nicole Gregoricus, Robert W. Frenck, Christine L. Moe, Mohamed S. Al-Ibrahim, Jill Barrett, Jennifer Ferreira, Mary K. Estes, David Y. Graham, Robert Goodwin, Astrid Borkowski, Ralf Clemens, and Paul M. Mendelman. Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. *The Journal of Infectious Diseases*, 211(6):870–878, March 2015. ISSN 0022-1899. doi: 10.1093/infdis/jiu497. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914500/>.
- Beate Schmoele-Thoma, Agnieszka M. Zareba, Qin Jiang, Mohan S. Maddur, Rana Danaf, Alex Mann, Kingsley Eze, Juin Fok-Seang, Golam Kabir, Andrew Catchpole, Daniel A. Scott, Alejandra C. Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, and Kena A. Swanson. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. *New England Journal of Medicine*, 386(25):2377–2386, June 2022. ISSN 0028-4793. doi: 10.1056/NEJMoa2116154. URL <https://www.nejm.org/doi/full/10.1056/NEJMoa2116154>.
- T Hope and J McMillan. Challenge studies of human volunteers: ethical issues. *Journal of Medical Ethics*, 30(1):110–116, February 2004. ISSN 0306-6800. doi: 10.1136/jme.2003.004440. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1757139/>.

- Constantine E. Frangakis and Donald B. Rubin. Principal Stratification in Causal Inference. *Biometrics*, 58(1):21–29, March 2002. ISSN 0006-341X. doi: 10.1111/j.0006-341x.2002.00021.x. URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137767/>.
- James Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. *Mathematical modelling*, 7(9-12):1393–1512, 1986. URL <https://www.sciencedirect.com/science/article/pii/0270025586900886>.
- Thomas S Richardson and James M Robins. Single world intervention graphs (SWIGs): A unification of the counterfactual and graphical approaches to causality. *Center for the Statistics and the Social Sciences, University of Washington Series. Working Paper*, 128(30):2013, 2013.
- Mats J. Stensrud, James M. Robins, Aaron Sarvet, Eric J. Tchetgen Tchetgen, and Jessica G. Young. Conditional Separable Effects. *Journal of the American Statistical Association*, 118(544):2671–2683, October 2023. ISSN 0162-1459. doi: 10.1080/01621459.2022.2071276. URL <https://doi.org/10.1080/01621459.2022.2071276>. Publisher: ASA Website eprint: <https://doi.org/10.1080/01621459.2022.2071276>.
- Mats J. Stensrud and Louisa Smith. Identification of Vaccine Effects When Exposure Status Is Unknown. *Epidemiology*, 34(2):216–224, March 2023. ISSN 1044-3983. doi: 10.1097/EDE.0000000000001573.
- Stephen J. Thomas, Edson D. Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbin, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper, Robert W. Frenck, Laura L. Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Qi Yang, Paul Liberator, Dina B. Tresnan, Susan Mather, Philip R. Dormitzer, Uğur Şahin, William C. Gruber, and Kathrin U. Jansen. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *New England Journal of Medicine*, 385(19):1761–1773, November 2021. ISSN 0028-4793. doi: 10.1056/NEJMoa2110345.
- Ming Zeng, Xu-Hu Mao, Jing-Xin Li, Wen-De Tong, Bin Wang, Yi-Ju Zhang, Gang Guo, Zhi-Jing Zhao, Liang Li, De-Lin Wu, Dong-Shui Lu, Zhong-Ming Tan, Hao-Yu Liang, Chao Wu, Da-Han Li, Ping Luo, Hao Zeng, Wei-Jun Zhang, Jin-Yu Zhang, Bo-Tao Guo, Feng-Cai Zhu, and Quan-Ming Zou. Efficacy, safety, and immunogenicity of an oral recombinant *Helicobacter pylori* vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, 386(10002):1457–1464, October 2015. ISSN 0140-6736, 1474-547X. doi: 10.1016/S0140-6736(15)60310-5.
- A. C. Davison and D. V. Hinkley. *Bootstrap Methods and their Application*. Cambridge Series in Statistical and Probabilistic Mathematics. Cambridge University Press, Cambridge, 1997. ISBN 978-0-521-57471-6. doi: 10.1017/CBO9780511802843.
- D. Katz, J. Baptista, S. P. Azen, and M. C. Pike. Obtaining Confidence Intervals for the Risk Ratio in Cohort Studies. *Biometrics*, 34(3):469–474, 1978. ISSN 0006-341X. doi: 10.2307/2530610. URL <https://www.jstor.org/stable/2530610>.
- Introduction. In Larry Wasserman, editor, *All of Nonparametric Statistics*, pages 1–11. Springer, New York, NY, 2006. ISBN 978-0-387-30623-0.

- R. J. Simes. An improved Bonferroni procedure for multiple tests of significance. *Biometrika*, 73(3):751–754, December 1986. ISSN 0006-3444. doi: 10.1093/biomet/73.3.751. URL <https://doi.org/10.1093/biomet/73.3.751>.
- Yoav Benjamini and Yosef Hochberg. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)*, 57(1):289–300, 1995. ISSN 0035-9246. URL <https://www.jstor.org/stable/2346101>. Publisher: [Royal Statistical Society, Oxford University Press].

ONLINE APPENDIX

A. Principal Strata at Different Times. Suppose that we are conducting a 4-arm trial, as described in Section 1 and depicted in Figure 2 of the main manuscript. Consider a counterfactual causal model such that there exists a pre-treatment variable, denoted by $T \in \{1, \dots, 16\}$, such that

$$\begin{aligned}
T = 1 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 2 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 3 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 4 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 5 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 6 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 7 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 8 &\implies (\Delta Y_1^{a=1,e_1=1} = 0, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 9 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 10 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 11 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 12 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 13 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 14 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1) \\
T = 15 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 0) \\
T = 16 &\implies (\Delta Y_1^{a=1,e_1=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1, \Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_2^{a=0,e_1=0,e_2=1} = 1)
\end{aligned}$$

The counterfactual groups above are a composite of the 4 conventional deterministic principal strata defined at each point in time. For example, someone may be doomed at time 1, while immune at time 2, which corresponds to $T = 4$. The transition from one principal stratum to another corresponds to a waning at the individual level, as one's response to exposure changes, at least under one of the two treatment levels.

In this general setting, the challenge effects are

$$VE_1^{\text{challenge}} = \frac{P(T \in \{9, \dots, 16\})}{P(T \in \{5, \dots, 8, 13, \dots, 16\})}$$

$$VE_2^{\text{challenge}} = \frac{P(T \in \{3, 4, 7, 8, 11, 12, 15, 16\})}{P(T \in \{2, 4, 6, 8, 10, 12, 14, 16\})},$$

which are equal to the observed incidence ratios under a suitable set of assumptions, as shown in Appendix B.

Corollary 1 (Principal Strata under the null). *Suppose Hypothesis 1 holds. Then*

$$P(T \in \{1, 6, 11, 16\}) = 1$$

Proof. Under the null hypothesis, and by partitioning

$$\begin{aligned} 0 &\stackrel{H_0}{=} P(\Delta Y_1^{a=1, e_1=1} = 0, \Delta Y_2^{a=1, e_1=0, e_2=1} = 1) \\ &= P(\Delta Y_1^{a=1, e_1=1} = 0, \Delta Y_1^{a=0, e_1=1} = 0, \Delta Y_2^{a=1, e_1=0, e_2=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 0) \\ &\quad + P(\Delta Y_1^{a=1, e_1=1} = 0, \Delta Y_1^{a=0, e_1=1} = 0, \Delta Y_2^{a=1, e_1=0, e_2=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 1) \\ &\quad + P(\Delta Y_1^{a=1, e_1=1} = 0, \Delta Y_1^{a=0, e_1=1} = 1, \Delta Y_2^{a=1, e_1=0, e_2=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 0) \\ &\quad + P(\Delta Y_1^{a=1, e_1=1} = 0, \Delta Y_1^{a=0, e_1=1} = 1, \Delta Y_2^{a=1, e_1=0, e_2=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 1). \end{aligned}$$

Therefore, by the axioms of probability $P(T = 3) = P(T = 4) = P(T = 7) = P(T = 8) = 0$. Similarly, under the null

$$\begin{aligned} P(\Delta Y_1^{a=1, e_1=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 0) &= P(\Delta Y_1^{a=0, e_1=1} = 0, \Delta Y_2^{a=0, e_1=0, e_2=1} = 1) \\ &= P(\Delta Y_1^{a=0, e_1=1} = 1, \Delta Y_2^{a=0, e_1=0, e_2=1} = 0) = 0, \end{aligned}$$

which implies that

$$\begin{aligned} P(T = 9) &= P(T = 10) = P(T = 13) = P(T = 14) = 0 \\ P(T = 2) &= P(T = 4) = P(T = 10) = P(T = 12) = 0 \\ P(T = 5) &= P(T = 7) = P(T = 13) = P(T = 15) = 0. \end{aligned}$$

Thus, we have that $P(T \in \{2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 15\}) = 0$, which means that $P(T \in \{1, 6, 11, 16\}) = 1$. \square

It follows that, under the null hypothesis, the challenge effects are equal to

$$\begin{aligned} VE_1^{\text{challenge}} &= \frac{P(T \in \{9, \dots, 16\})}{P(T \in \{5, \dots, 8, 13, \dots, 16\})} \stackrel{H_0}{=} \frac{P(T \in \{11, 16\})}{P(T \in \{6, 16\})} \\ VE_2^{\text{challenge}} &= \frac{P(T \in \{3, 4, 7, 8, 11, 12, 15, 16\})}{P(T \in \{2, 4, 6, 8, 10, 12, 14, 16\})} \stackrel{H_0}{=} \frac{P(T \in \{11, 16\})}{P(T \in \{6, 16\})}, \end{aligned}$$

which shows their equality under the null.

We argue for the equivalence of the population level and the sharp no waning, under the sharp no waning of the placebo, that is, $\Delta Y_1^{a=0, e_1=1} = \Delta Y_2^{a=0, e_1=0, e_2=1}$ with probability 1. We believe this is a plausible assumption, as the effect of the placebo should not change over time for an individual if they are isolated; hence, their immune system is

not challenged before the exposure. Therefore, if they were to develop the outcome upon exposure at time 1, then they would develop it at time 2, given that the exposures are identical. Similarly, if they were to remain event-free at time 1 due to natural immunity, for example, due to genetic reasons, a quality that would not change over time and they would remain event-free at time 2 as well.

By identical arguments as in the proof above, the sharp no waning of the placebo implies that

$$P(T \in \{2, 4, 5, 7, 10, 12, 13, 15\}) = 0.$$

In this setting, the challenge effects are

$$\begin{aligned} VE_1^{\text{challenge}} &= \frac{P(T \in \{9, \dots, 16\})}{P(T \in \{5, \dots, 8, 13, \dots, 16\})} = \frac{P(T \in \{9, 11, 14, 16\})}{P(T \in \{6, 8, 14, 16\})} \\ VE_2^{\text{challenge}} &= \frac{P(T \in \{3, 4, 7, 8, 11, 12, 15, 16\})}{P(T \in \{2, 4, 6, 8, 10, 12, 14, 16\})} = \frac{P(T \in \{3, 8, 11, 16\})}{P(T \in \{6, 8, 14, 16\})}. \end{aligned}$$

Therefore, $VE_1^{\text{challenge}} = VE_2^{\text{challenge}}$, when the null hypothesis does not hold, if and only if $(T \in \{9, 11, 14, 16\}) = (T \in \{3, 8, 11, 16\})$, that is equivalent to

$$P(T = 9) + P(T = 14) = P(T = 3) + P(T = 8).$$

In words, the population-level challenge effects are equal, despite individual-level waning, if the probability of transitioning from harmed to immune or from doomed to helped is equal to the probability of transitioning from immune to harmed or from harmed to doomed. Informally, this implies that in the treatment arm, the same number of people experience positive waning of the vaccine as the number of people who experience negative waning. In general, it is unlikely that the vaccine improves over time $P(T \in \{9, 14\}) \approx 0$; thus, equivalence between the null hypothesis of individual no waning and population no waning is plausible.

B. Proof of Proposition 1.

Proof. The observed incidence rate ratio at time 1 is equal to

$$\begin{aligned}
1 - VE_1^{\text{challenge}} &:= \frac{E[\Delta Y_1^{a=1, e_1=1}]}{E[\Delta Y_1^{a=0, e_1=1}]} \\
&\stackrel{\text{Assumption 4}}{=} \frac{E[\Delta Y_1^{a=1, e_1=1} | E_1^{a=1} = 1]}{E[\Delta Y_1^{a=0, e_1=1} | E_1^{a=0} = 1]} \\
&\stackrel{\text{Assumption 7}}{=} \frac{E[\Delta Y_1^{a=1} | E_1^{a=1} = 1]}{E[\Delta Y_1^{a=0} | E_1^{a=0} = 1]} \\
&\stackrel{\text{Assumption 1}}{=} \frac{E[\Delta Y_1^{a=1}] / P(E_1^{a=1} = 1)}{E[\Delta Y_1^{a=0}] / P(E_1^{a=0} = 1)} \\
&\stackrel{\text{Assumption 3}}{=} \frac{E[\Delta Y_1^{a=1}]}{E[\Delta Y_1^{a=0}]} \\
&\stackrel{\text{Assumption 8, 9}}{=} \frac{E[\Delta Y_1^{a=1} | A = 1]}{E[\Delta Y_1^{a=0} | A = 0]} \\
&\stackrel{\text{Assumption 7}}{=} \frac{E[\Delta Y_1 | A = 1]}{E[\Delta Y_1 | A = 0]}
\end{aligned}$$

At time 2, the incidence rate for the arm $A = a$ is

$$\begin{aligned}
E[\Delta Y_2 | A = a] &\stackrel{\text{Assumption 7, 8, 9}}{=} E[\Delta Y_2^a] \\
&= E[\Delta Y_2^a | E_1^a = 0] P(E_1^a = 0) \\
&\quad + E[\Delta Y_2^a | E_1^a = 1] P(E_1^a = 1).
\end{aligned}$$

Considering the first term

$$\begin{aligned}
E[\Delta Y_2^a | E_1^a = 0] P(E_1^a = 0) &\stackrel{\text{Assumption 1}}{=} E[\Delta Y_2^a | E_1^a = 0, E_2^a = 1] P(E_2^a = 1 | E_1^a = 0) P(E_1^a = 0) \\
&\stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a, e_1=0} | E_1^a = 0, E_2^{a, e_1=0} = 1] P(E_2^{a, e_1=0} = 1 | E_1^a = 0) \\
&\quad \times P(E_1^a = 0) \\
&\stackrel{\text{Assumption 4}}{=} E[\Delta Y_2^{a, e_1=0} | E_2^{a, e_1=0} = 1] P(E_2^{a, e_1=0} = 1 | E_1^a = 0) P(E_1^a = 0) \\
&\stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a, e_1=0, e_2=1} | E_2^{a, e_1=0} = 1] P(E_2^{a, e_1=0} = 1, E_1^a = 0) \\
&\stackrel{\text{Assumption 4}}{=} E[\Delta Y_2^{a, e_1=0, e_2=1}] P(E_2^{a, e_1=0} = 1, E_1^a = 0).
\end{aligned}$$

The second term equals

$$\begin{aligned}
(3) \quad E[\Delta Y_2^a | E_1^a = 1] P(E_1^a = 1) &= E[\Delta Y_2^a | E_1^a = 1, \Delta Y_1^a = 0] P(\Delta Y_1^a = 0 | E_1^a = 1) P(E_1^a = 1) \\
&\stackrel{\text{Assumption 1}}{=} E[\Delta Y_2^a | E_1^a = 1, \Delta Y_1^a = 0, E_2^a = 1] \\
&\quad \times P(E_2^a = 1 | E_1^a = 1, \Delta Y_1^a = 0) P(\Delta Y_1^a = 0 | E_1^a = 1) P(E_1^a = 1) \\
&\stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a, e_1=1} | E_1^a = 1, \Delta Y_1^{a, e_1=1} = 0, E_2^{a, e_1=1} = 1] \\
&\quad \times P(E_2^{a, e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a, e_1=1} = 0) P(\Delta Y_1^{a, e_1=1} = 0 | E_1^a = 1) \\
&\quad \times P(E_1^a = 1)
\end{aligned}$$

Using Assumption 7

$$\begin{aligned} & E[\Delta Y_2^{a,e_1=1} | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1} = 1] \\ &= E[\Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1} | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1,\delta y_1=0} = 1]. \end{aligned}$$

As shown in Remark 1, under Assumption 2 and the null hypothesis, $\Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1} = \Delta Y_1^{a,e_1=1}$. Therefore

$$E[\Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1} | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1,\delta y_1=0} = 1] = 0,$$

which shows that $E[\Delta Y_2^a | E_1^a = 1]P(E_1^a = 1) = 0$. Finally,

$$\begin{aligned} \frac{E[\Delta Y_2 | A = 1]}{E[\Delta Y_2 | A = 1]} &= \frac{E[\Delta Y_2^{a=1} | E_1^{a=1} = 0]P(E_1^{a=1} = 0)}{E[\Delta Y_2^{a=0} | E_1^{a=0} = 0]P(E_1^{a=0} = 0)} \\ &= \frac{E[\Delta Y_2^{a=1,e_1=0,e_2=1}]P(E_2^{a=1,e_1=0} = 1, E_1^{a=1} = 0)}{E[\Delta Y_2^{a=0,e_1=0,e_2=1}]P(E_2^{a=0,e_1=0} = 1, E_1^{a=0} = 0)} \\ &\stackrel{\text{Assumption 3}}{=} \frac{E[\Delta Y_2^{a=1,e_1=0,e_2=1}]}{E[\Delta Y_2^{a=0,e_1=0,e_2=1}]} := 1 - VE_2^{\text{challenge}} \end{aligned}$$

Under the null hypothesis $E[\Delta Y_1^{a,e_1=1}] = E[\Delta Y_2^{a,e_1=0,e_2=1}]$, which implies $VE_1^{\text{challenge}} = VE_2^{\text{challenge}}$, and thus the equality $IR_1 = IR_2$ holds. \square

C. Simulation. Consider the following data-generating mechanism

$$\begin{aligned} A &:= \text{Bernoulli}(0.5) \\ T_1 &:= \text{Categorical}(p_{\text{doomed}_1}, p_{\text{helped}_1}, p_{\text{harmed}_1}, p_{\text{immune}_1}) \\ E_1 &:= \text{Bernoulli}(p_{E_1}) \\ \Delta Y_1 &:= E_1 \times (I(T_1 = 1) + (1 - A) \times I(T_1 = 2) + A \times I(T_1 = 3)) \\ E_2 &:= (1 - \Delta Y_1) \times \text{Bernoulli}(p_{E_2}) \\ \Delta Y_2 &:= E_2 \times (I(T_2 = 1) + (1 - A) \times I(T_2 = 2) + A \times I(T_2 = 3)). \end{aligned}$$

Here, T_1 corresponds to the 4 standard principal strata, as discussed in Appendix A. While the proof and the assumptions of Proposition 1 do not rely on the notion of the principal strata, to simulate the observed outcomes while respecting the constraints imposed on the challenge effects commonly involves assigning to all individuals their potential outcomes under all treatment levels and realizing their observed data by simulating the observed treatment. Furthermore, T_2 is determined in a way to decrease the first interval challenge effect $VE_1^{\text{challenge}} = 1 - \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{doomed}_1} + p_{\text{helped}_1}}$ such that we randomly resample a proportion of the helped individuals as doomed, to satisfy the assumption of sharp no waning of the placebo. The proportion is calculated, such that it is ensured in expectation that $\frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{doomed}_1} + p_{\text{helped}_1}} \times w = \frac{p_{\text{doomed}_2} + p_{\text{harmed}_2}}{p_{\text{doomed}_2} + p_{\text{helped}_2}}$ for some factor $w > 1$, (with $w = 1$ corresponding to the sharp null hypothesis) (see Appendix C.2 for details). $T = 1, 2, 3, 4$ are defined to correspond to being *doomed*, *helped*, *harmed*, and *immune*, respectively.

By Proposition 1, the two incidence ratios are equal when the sharp null hypothesis holds. Therefore, we can test whether $IR_1/IR_2 = 1$ to assess the null hypothesis.




FIGURE 4. Rejection rate of the test statistics at level $\alpha = 0.05$ from 100 simulations. The rows correspond to the direct δ -method, the conservative δ -method, and the non-parametric bootstrap, respectively.

We propose three alternative methods to construct the confidence interval for the fraction of the incidence ratios. We can approximate the four empirical means, corresponding to the expected outcome at the first and the second time under treatment vs no treatment, respectively, as log-normal distributions. We can calculate the variance of both IR_1 and IR_2 using the δ -method; however, the incidence ratios are negatively correlated,

which depends on the level of exposure and the distribution of the susceptibility. To have a valid confidence interval, the correlation can be lower bounded by -1 , but this is a considerable over-approximation when exposure is low or moderate, and when the population is heterogeneous in terms of susceptibility. To provide more precise confidence intervals, we can use the δ -method to derive a direct estimator for the variance of $\log(\widehat{IR}_1) - \log(\widehat{IR}_2)$. Details of both are provided in Appendix G. Finally, given that we have access to patient-level data, we can derive the bounds using non-parametric bootstrap methods (Davison and Hinkley, 1997).

Figure 4 illustrates the performance of the derived test statistics using the three alternatives. We set the baseline vaccine effect to $VE_1^{\text{challenge}} = 0.5$, by simulating T_1 from $\text{Categorical}(0.2, 0.6, 0.2, 0)$. Under the varying level of exposure $E_1 = E_2 \in \{0.1, 0.3, 0.9\}$, the level of overestimation of the variance is changing as illustrated in the first row. In particular, for relatively low exposure, $E_1 = E_2 = 0.1$, the test is more conservative, and for low sample size, the null hypothesis is rejected at the level of the test, even when waning is substantial, that is, the vaccine effect decreases to $VE = 0.05$. However, when the correlation approaches the supposed lower bound, by $E_1 = E_2 = 0.9$, the null hypothesis is rejected at a rate of 0.54, even for a moderate sample size of $n = 1000$, and limited waning, $VE_1 = 0.5$, $VE_2 = 0.35$. In any of the simulated scenarios, when the null hypothesis holds, the test rejects at a rate below its level.

Deriving the confidence interval using non-parametric bootstrap has greater power than using the direct δ -method. However, the δ -method maintains the nominal level, while the bootstrap shows deviations from it.

Extension to the time-to-event framework is trivial, except that the waning cannot be entirely continuous; the transition from one's reaction to exposure to a different reaction can be achieved in a discrete manner. Similar to the original paper of Janvin et al. (2024), we can estimate the event rates using the cumulative hazard. Whether exposure is recurring or a single one does not matter, since under the null hypothesis, the outcome will be deterministically the same following each exposure.

As discussed in Section 3, the equality of the hazard ratios is unsuitable for testing the waning of the vaccine effect, informally, due to the depletion of susceptibles over time. Using the same simulated data, we constructed confidence intervals for $\widehat{HR}_1/\widehat{HR}_2$ using non-parametric bootstrap, to test $HR_1/HR_2 = 1$.

Figure 5 shows that when exposure is low, and hence the depletion of susceptibles is minor, the test based on hazard ratios is comparable to the test using incidence ratios, see Subfigure 4 C. However, when the level of infectious pressure increases by exposure, when the null hypothesis holds ($w = 0$), the test does not hold its nominal level. In addition, the power of the test does not increase with the level of the waning, which arguably is a desirable property of any sensible test of waning.

C.1. Sensitivity analysis. Consider the same data-generating mechanism as in the main part of Appendix C, except for T_1 and T_2 . As opposed to the simulation shown in the main part of the manuscript, suppose

$$T_1 \sim \text{Categorical}(0.2, 0.4, 0.1, 0.3).$$




FIGURE 5. Rejection rates of the test statistics for $\widehat{HR}_1/\widehat{HR}_2$ at level $\alpha = 0.05$, compared to IR based test statistics, from 100 simulations, using non-parametric bootstrap.

Under the assumption of sharp no waning of the placebo, we will consider three different scenarios for determining T_2 , when the individual-level vaccine effect decreases:

- Transitioning a proportion of helped-to-doomed ($w_{immune}^* = 0$), which corresponds to the setting depicted in Figure 4, however, under a different distribution of T_1 .
- Transitioning a proportion of immune-to-harmed ($w_{helped}^* = 0$).
- Transitioning an equal proportion of helped and immune to doomed and harmed, respectively ($w_{helped}^* = w_{immune}^*$).

For details of determining the exact proportions w^* to match the desired amount of waning w , see Appendix C.2.

The simulation results are shown in Figures 6, 7, and 8.

When we include immune individuals in our cohort, by lowering the incidence rates of the outcomes, the variance of the estimator increases.

Comparing Figure 6 to 7, we can see that restricting the waning to helped-to-doomed,




FIGURE 6. Rejection rates under helped-to-doomed transitions.

Finally, even though we allow for unmeasured confounding between the exposures over time, for simplicity, we omitted that from the simulations. Consider the modified data-generating mechanism

$$\begin{aligned}
 A &:= \text{Bernoulli}(0.5) \\
 U_E &:= \text{Bernoulli}(0.5) \\
 T_1 &:= \text{Categorical}(p_{\text{doomed}_1}, p_{\text{helped}_1}, p_{\text{harmed}_1}, p_{\text{immune}_1}) \\
 E_1 &:= U_E \times \text{Bernoulli}(p_{E_{\text{high}}}) + (1 - U_E) \times \text{Bernoulli}(p_{E_{\text{low}}}) \\
 \Delta Y_1 &:= E_1 \times (I(T_1 = 1) + (1 - A) \times I(T_1 = 2) + A \times I(T_1 = 3)) \\
 E_2 &:= (1 - \Delta Y_1) \times (U_E \times \text{Bernoulli}(p_{E_{\text{high}}}) + (1 - U_E) \times \text{Bernoulli}(p_{E_{\text{low}}})) \\
 \Delta Y_2 &:= E_2 \times (I(T_2 = 1) + (1 - A) \times I(T_2 = 2) + A \times I(T_2 = 3))
 \end{aligned}$$




FIGURE 7. Rejection rates under immune-to-harmed transitions.

The binary confounder assigns each individual to exposure-seeking or exposure-averse behaviors. However, our test is valid, even when such confounding exists, as shown in Figure 9. T_1 is distributed as in the main analysis, and waning happens only through helped-to-doomed transitions. We fix $p_{E_{low}} = 0.1$ and vary $p_{E_{high}} \in \{0.1, 0.3, 0.9\}$.

In all four modified scenarios, the power gain by using the direct δ -method instead of the conservative approach is pronounced. The direct δ -method has rejection rates approximately at the level of the test statistics, while in the case of the non-parametric bootstrap, larger deviations can happen. In general, we argue for the usage of the direct δ -method, since it is feasible using summary data only, and has acceptable power, while maintaining the validity of the test.

C.2. Determining transition rates. In Appendix C we simulate data, such that the distribution of the principal strata changes from time 1 to time 2. In particular, the “challenge




FIGURE 8. Rejection rates under equal helped-to-doomed and immune-to-harmed transitions.

incidence ratio” should increase, that is, the incidence ratio should increase by a factor w from time 1 to time 2 if we compare a population exposed at time 1 to a population that has been isolated first and then exposed at time 2. Consequently, the change in the principal strata, should be independent of all other variables.

We argued in Section 3, that the sharp null hypothesis is equivalent to the population level null hypothesis, under a set of conditions, one of which is sharp no waning of the placebo. That is, the individual level potential outcome will not change from time 1 to time 2 when intervening on treatment and exposure. Therefore, the only possible transitions are from “doomed” to “helped”, “helped” to “doomed”, “harmed” to “immune”, and “immune” to “harmed”. The waning of the vaccine, that is, the decrease in efficacy, corresponds to transitions from helped to doomed and immune to harmed (although, if for some, the vaccine efficacy increased, but for a larger proportion of the population it




FIGURE 9. Rejection rates with confounded exposures.

decreased, the vaccine still waned at a population level). For simplicity, in Appendix C we only illustrated the results for the transition helped to doomed. Simulation results with alternative waning are available in Appendix C.1.

The incidence ratios in the challenge sense are

$$IR_1^{\text{challenge}} = \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{doomed}_1} + p_{\text{helped}_1}} \quad IR_2^{\text{challenge}} = \frac{p_{\text{doomed}_2} + p_{\text{harmed}_2}}{p_{\text{doomed}_2} + p_{\text{helped}_2}}.$$

Suppose that the incidence rate increased by a factor of w between the two time-points, due to the transitions helped to doomed and immune to harmed. In particular, suppose that a proportion w_{helped}^* of the helped transitioned to doomed, a proportion w_{immune}^* of

the immune transitioned to harmed. Then the time 2 incidence ratio can be rewritten as

$$\begin{aligned} IR_2^{\text{challenge}} &= w \times \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{doomed}_1} + p_{\text{helped}_1}} \\ &= \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1} + w_{\text{helped}}^* \times p_{\text{helped}_1} + w_{\text{immune}}^* \times p_{\text{immune}_1}}{p_{\text{doomed}_1} + p_{\text{helped}_1}}. \end{aligned}$$

Solving for w_{helped}^* , w_{immune}^* , we have

$$(4) \quad w_{\text{helped}}^* \times p_{\text{helped}_1} + w_{\text{immune}}^* \times p_{\text{immune}_1} = (w - 1) \times (p_{\text{doomed}_1} + p_{\text{harmed}_1}).$$

Thus, when the only transition happening is helped to doomed,

$$w_{\text{helped}}^* = (w - 1) \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{helped}_1}},$$

and when the only transition is from immune to harmed,

$$w_{\text{immune}}^* = (w - 1) \frac{p_{\text{doomed}_1} + p_{\text{harmed}_1}}{p_{\text{immune}_1}}.$$

From Equation 4 it is clear, that when $w = 1$, that is, the sharp null hypothesis holds, there is no transition from either of the two possible principal strata.

D. Interpretation of the IR, under the alternative. Suppose that Hypothesis 1 does not hold, that is, $\Delta Y_2^{a,e_1=0,e_2=1}$ and $\Delta Y_1^{a,e_1=1}$ can potentially differ. Under Assumptions 1 and 3, by identical arguments as in Appendix B, we can show that $IR_1 = 1 - VE_1^{\text{challenge}}$. Since $IR_1 = HR_1$, our result agrees with the point identification claim of Janvin et al. (2024).

By the same reasoning as in Appendix B, we can show that under Assumptions 1-4, 7-9

$$\begin{aligned} E[\Delta Y_2 | A = a] &= E[\Delta Y_2^a | E_1^a = 0]P(E_1^a = 0) \\ &\quad + E[\Delta Y_2^a | E_1^a = 1]P(E_1^a = 1), \end{aligned}$$

and that

$$E[\Delta Y_2^a | E_1^a = 0]P(E_1^a = 0) = E[\Delta Y_2^{a,e_1=0,e_2=1}]P(E_2^{a,e_1=0} = 1, E_1^a = 0).$$

However, under the alternative of the null hypothesis $E[\Delta Y_2^a | E_1^a = 1]P(E_1^a = 1)$ is not necessarily equal to 0. In addition to the previously presented assumptions, suppose the following:

Assumption 5 (Extended exposure exchangeability).

$$\begin{aligned} E_1^a &\perp\!\!\!\perp \Delta Y_2^{a,e_1=1} | \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1} \\ \text{and} \quad E_2^{a,e_1=1} &\perp\!\!\!\perp \Delta Y_2^{a,e_1=1,e_2} | \Delta Y_1^{a,e_1=1} = 0 \end{aligned}$$

Assumption 5 generalizes Assumption 4 such that it holds under the intervention $e_1 = 1$. While previously, by Assumption 1, the intervention $e_1 = 0$ resulted in implicit conditioning on $\Delta Y_1^{a,e_1=0} = 0$, since under $e_1 = 1$, the time 1 outcome is not

deterministically 0, we have to condition on it explicitly. Both Assumptions 4 and 5 hold under the DAG proposed by Janvin et al. (2024), reproduced in Figure 11.

Continuing with Equation 3

$$\begin{aligned}
& E[\Delta Y_2^{a,e_1=1} | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1} = 1] \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(\Delta Y_1^{a,e_1=1} = 0 | E_1^a = 1) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 5}}{=} E[\Delta Y_2^{a,e_1=1} | \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1} = 1] \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(\Delta Y_1^{a,e_1=1} = 0 | E_1^a = 1) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a,e_1=1,e_2=1} | \Delta Y_1^{a,e_1=1} = 0, E_2^{a,e_1=1} = 1] \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(\Delta Y_1^{a,e_1=1} = 0 | E_1^a = 1) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 5}}{=} E[\Delta Y_2^{a,e_1=1,e_2=1} | \Delta Y_1^{a,e_1=1} = 0] P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) \\
& \times P(\Delta Y_1^{a,e_1=1} = 0 | E_1^a = 1) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 4}}{=} E[\Delta Y_2^{a,e_1=1,e_2=1} | \Delta Y_1^{a,e_1=1} = 0] P(\Delta Y_1^{a,e_1=1} = 0) \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a,e_1=1,\delta y_1=0,e_2=1} | \Delta Y_1^{a,e_1=1} = 0] P(\Delta Y_1^{a,e_1=1} = 0) \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(E_1^a = 1) \\
& \stackrel{\text{Assumption 2}}{=} E[\Delta Y_2^{a,e_1=0,e_2=1} | \Delta Y_1^{a,e_1=1} = 0] P(\Delta Y_1^{a,e_1=1} = 0) \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(E_1^a = 1) \\
& = P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0) \\
& \times P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) P(E_1^a = 1)
\end{aligned}$$

Under the null hypothesis, the joint probability,

$$P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0)$$

is equal to 0; however, under the alternative, not necessarily.

Therefore,

$$\begin{aligned}
(5) \quad E[\Delta Y_2 | A = a] &= P(\Delta Y_2^{a,e_1=0,e_2=1} = 1) P(E_2^{a,e_1=0} = 1 | E_1^a = 0, \Delta Y_1^{a,e_1=0} = 0) P(E_1^a = 0) \\
&+ P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0) P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0) \\
&\times P(E_1^a = 1)
\end{aligned}$$

and

$$IR_2 = \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1) p_0^{2,a=1} p_0^1 + P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0) p_1^{2,a=1} p_1^1}{P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1) p_0^{2,a=0} p_0^1 + P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0) p_1^{2,a=0} p_1^1},$$

where $p_{e_1}^a = P(E_2^{a,e_1} = 1 | E_1^a = e_1, \Delta Y_1^{a,e_1} = 0)$ and $p_{e_1}^1 = P(E_1^a = e_1) \stackrel{\text{Assumption 3}}{=} P(E_1 = e_1)$.

Depending on the exposure probabilities, $P(\Delta Y_2^{a,e_1=0,e_2=1} = 1)$, and $P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0)$, IR_2 can be either below or above the $VE_2^{\text{challenge}}$, thus IR_2 is uninformative about the extent of the waning.

Assumption 6 (Sharp no waning of the placebo).

$$\Delta Y_2^{a=0,e_1=0,e_2=1} = \Delta Y_1^{a,e_1=1} \quad \text{w.p 1.}$$

Assumption 6 was used to establish equivalence between individual and population waning in Remark 2. Under the alternative and Assumption 6, we allow for $\Delta Y_2^{a=1,e_1=0,e_2=1} \neq \Delta Y_1^{a=1,e_1=1}$ with a non-zero probability.

By Assumption 6

$$\begin{aligned} IR_2 &= \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1)p_0^{2,a=1}p_0^1 + P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^{2,a=1}p_1^1}{P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1)p_0^{2,a=0}p_0^1} \\ &= \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1)p_0^{2,a=1}p_0^1}{P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1)p_0^{2,a=0}p_0^1} + \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^{2,a=1}p_1^1}{P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1)p_0^{2,a=0}p_0^1} \\ &= 1 - VE_2^{\text{challenge}} + \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^{2,a=1}p_1^1}{P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1)p_0^{2,a=0}p_0^1}. \end{aligned}$$

In other words, under Assumption 6 and the alternative, the second timepoint incidence ratio overestimates $1 - VE_2^{\text{challenge}}$. The size of the overestimation depends on the exposure probabilities and the size of the principal strata, which corresponds to individuals who transitioned from immune to harmed or from helped to doomed. Those who experienced the improvement of the vaccine over time (doomed to helped and harmed to immune) do not add to the bias, since even if they remained event-free in time 1, in the second interval they do not develop the outcome under treatment, that is the same outcome that they would have experienced, had they been isolated at time 1.

Due to the sign of the bias, when $IR_1 < IR_2$, that is, based on the incidence ratios, the vaccine seemingly wanes, $VE_1^{\text{challenge}} < VE_2^{\text{challenge}}$ can still hold. The qualitative difference between the incidence ratio and the challenge effects, under Assumption 6, can occur if

$$P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_1^{a=1,e_1} = 1) > P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1} = 0),$$

that is, the probability of the effect of the individual vaccine improvement is greater than the probability of individual waning, and

$$\begin{aligned} &P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1} = 0)(p_0^{2,a=1}p_0^1 + p_1^{2,a=1}p_1^1) \\ &> P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_1^{a=1,e_1} = 1)p_0^{2,a=1}p_0^1. \end{aligned}$$

Assuming independence between the exposures, given survival ($E_1^a \perp\!\!\!\perp E_2^{a,e_1} | \Delta Y_1^{a,e_1} = 0$, similar to Equation 7 of Janvin et al. (2024)), $p_1^{2,a} = p_0^{2,a}$ follows and the second condition simplifies to

$$P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1} = 0) > P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 0, \Delta Y_1^{a=1,e_1} = 1)p_0^1.$$

Therefore, if the extent of waning is substantial compared to vaccine improvement and the infectious pressure at time 1 is high, waning could be mistakenly claimed based on the incidence ratios, even though the challenge effect has increased over time.

If $IR_2 < IR_1$, then due to the positive bias of IR_2 , $VE_2^{\text{challenge}} > VE_1^{\text{challenge}}$, that is, if the vaccine seemingly improved based on the incidence ratios, indeed the vaccine improved in the challenge effect sense. However, the size of this improvement is overestimated by the incidence ratios, with the magnitude of the overestimation depending on the probability of vaccine waning and the exposure probabilities.

D.1. *Sensitivity analysis on the challenge effects.* From Equation 5 it follows that

$$P(\Delta Y_2^{a,e_1=0,e_2=1} = 1)p_0^{2,a}p_0^1 = E[\Delta Y_2|A=a] - P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0)p_1^{2,a}p_1^1.$$

Under Assumption 3 and 7, $p_0^{2,a=1}p_0^1 = p_0^{2,a=0}p_0^1$, thus

$$(6) \quad 1 - VE_2^{\text{challenge}} = \frac{E[\Delta Y_2|A=1] - P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^{2,a=1}p_1^1}{E[\Delta Y_2|A=0] - P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0)p_1^{2,a=0}p_1^1}.$$

Using information from the observed data and Assumption 6, we can bound some of the expressions in Equation 6. As

$$E[Y_2|A=a] = (P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0) + P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 1))p_0^2p_0^1 + P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0)p_1^2p_1^1,$$

thus

$$(7) \quad P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=1} = 0) \leq \frac{E[\Delta Y_2|A=a]}{p_0^2p_0^1 + p_1^2p_1^1}.$$

Under Assumption 6 $P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1, \Delta Y_1^{a=0,e_1=1} = 0) = 0$, thus

$$E[\Delta Y_1|A=0] = P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1)p_1^1$$

and

$$E[\Delta Y_2|A=0] = P(\Delta Y_2^{a=0,e_1=0,e_2=1} = 1, \Delta Y_1^{a=0,e_1=1} = 1)p_0^2(1 - p_1^1),$$

implying that the equality

$$(8) \quad \frac{E[\Delta Y_1|A=0]}{E[\Delta Y_2|A=0]} = \frac{p_1^1}{p_0^2(1 - p_1^1)}$$

must hold.

Since under Assumption 6

$$VE_2^{\text{challenge}} = 1 - IR_2 + \frac{P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^2p_1^1}{E[\Delta Y_2|A=0]},$$

$VE_2^{\text{challenge}}$ is maximized when $P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0)p_1^2p_1^1 - E[\Delta Y_2|A=1]$ reaches its maximum. By Equation (7), the maximum is reached at $P(\Delta Y_2^{a=1,e_1=0,e_2=1} = 1, \Delta Y_1^{a=1,e_1=1} = 0) = \frac{E[\Delta Y_2|A=1]}{p_0^2p_0^1 + p_1^2p_1^1}$, thus it is equal to

$$E[\Delta Y_2|A=1] \frac{p_1^2p_1^1 - p_0^2p_0^1 - p_1^2p_1^1}{p_0^2p_0^1 + p_1^2p_1^1} = E[\Delta Y_2|A=1] \frac{-p_0^2p_0^1}{p_0^2p_0^1 + p_1^2p_1^1}.$$

By Equation (8),

$$p_1^1 = \frac{E[\Delta Y_1 | A = 0] p_0^2}{E[\Delta Y_2 | A = 0] + E[\Delta Y_1 | A = 0] p_0^2} \quad \text{and} \quad p_0^1 = \frac{E[\Delta Y_2 | A = 0]}{E[\Delta Y_2 | A = 0] + E[\Delta Y_1 | A = 0] p_0^2},$$

thus, the maximum simplifies to

$$\begin{aligned} & E[\Delta Y_2 | A = 1] \frac{-p_0^2 E[\Delta Y_2 | A = 0]}{p_0^2 E[\Delta Y_2 | A = 0] + p_1^2 E[\Delta Y_1 | A = 0] p_0^2} \\ &= E[\Delta Y_2 | A = 1] \frac{-E[\Delta Y_2 | A = 0]}{E[\Delta Y_2 | A = 0] + p_1^2 E[\Delta Y_1 | A = 0]}. \end{aligned}$$

Since all expectations are non-negative, the fraction increases in p_1^2 ; therefore, it reaches its maximum at $p_1^2 = 1$. Then,

$$\begin{aligned} V E_2^{\text{challenge}} &\leq 1 + \frac{E[\Delta Y_2 | A = 1]}{E[\Delta Y_2 | A = 0]} \frac{-E[\Delta Y_2 | A = 0]}{E[\Delta Y_2 | A = 0] + p_1^2 E[\Delta Y_1 | A = 0]} \Big|_{p_1^2=1} \\ &= 1 - \frac{E[Y_2 | A = 1]}{E[Y_1 | A = 0] + E[Y_2 | A = 0]}, \end{aligned}$$

which is the same upper bound on the challenge effect as derived by Janvin et al. (2024). However, if data are available from a standard RCT and there is knowledge about the probability $P(E_2^{a,e_1=1} = 1 | E_1^a = 1, \Delta Y_1^{a,e_1=1} = 0)$, for example, from contact tracing studies, the upper bound can be considerably improved.

To illustrate the result, we took the observed quantities $E[Y_1 | A = 0]$, $E[Y_1 | A = 1]$, $E[Y_2 | A = 0]$, and $E[Y_2 | A = 1]$ from the BNT162b2 trial Thomas et al. (2021), and plotted the upper bound under the changing values of p_1^2 in Figure 10

E. On the Assumptions of Janvin et al. (2024). Similar to Janvin et al. (2024), because we consider data from a randomized controlled trial, we take the following three conventional assumptions for granted:

Assumption 7 (Consistency). Suppose that the interventions on the treatment A , exposures E_1 , E_2 , and the first timepoint survival $\Delta Y_1 = 0$ are well-defined. That is

- (i) if $A = a$ then $E_1 = E_1^a$, $\Delta Y_1 = \Delta Y_1^a$, $E_2 = E_2^a$, $\Delta Y_2 = \Delta Y_2^a$,
- (ii) if $E_1^a = e_1$ then $\Delta Y_1^a = \Delta Y_1^{a,e_1}$, $E_2^a = E_2^{a,e_1}$, $\Delta Y_2^a = \Delta Y_2^{a,e_1}$,
- (iii) if $\Delta Y_1^{a,e_1} = 0$ then $E_2^{a,e_1} = E_2^{a,e_1,\delta y_1=0}$, $\Delta Y_2^{a,e_1} = \Delta Y_2^{a,e_1,\delta y_1=0}$,
- (iv) if $E_2^{a,e_1,\delta y_1=0} = e_2$ then $\Delta Y_2^{a,e_1,\delta y_1=0} = \Delta Y_2^{a,e_1,\delta y_1=0,e_2}$,
- (v) if $E_2^{a,e_1=0} = e_2$ then $\Delta Y_2^{a,e_1=0} = \Delta Y_2^{a,e_1=0,e_2}$,

for all $a, e_1, e_2 \in \{0, 1\}$.

Assumption 8 (Treatment exchangeability).

$$E_1^a, \Delta Y_1^a, \Delta Y_1^{a,e_1}, E_2^{a,e_1}, E_2^{a,e_1,\delta y_1=0}, \Delta Y_2^{a,e_1,\delta y_1=0,e_2} \perp\!\!\!\perp A$$

for all $a, e_1, e_2 \in \{0, 1\}$.

Assumption 9 (Positivity).

$$P(A = a) > 0 \quad \text{for all } a \in \{0, 1\}.$$




FIGURE 10. The changing value on the upper bound of $VE_2^{\text{challenge}}$ (solid red line), for some p_1^2 , with the corresponding one-sides 95% confidence interval (dashed red). $VE_1^{\text{challenge}}$ (solid black), is point-identified, regardless of the value of p_1^2 or other exposure probabilities. A dashed black line represents the corresponding 95% two-sided confidence interval. The values at p_1^2 are equal to the findings of Janvin et al. (2024).

Assumptions 7-9 are close to the RCT assumptions set by Janvin et al. (2024). The most important distinction is that we suppose it is possible to intervene on ΔY_1 , with a well-defined intervention; thus, consistency holds if $\Delta Y_1 = 0$. Accordingly, we state the treatment exchangeability assumption for potential outcomes under the intervention $\delta y_1 = 0$.

Assumption 1 states that in order to develop the outcome at a given timepoint, exposure at the same timepoint should have happened. The version stated in the main document is stronger than the one proposed by Janvin et al. (2024): Assumption 1 needs to hold even if there was no intervention at time 1 isolating the individuals. That is, there can be no causal effect of time 1 exposure at the time 2 outcome, that is not mediated through ΔY_1 or E_2 , which is also a sufficient condition for Assumption 2.

While Assumption 8 already imposed structural constraints on the relationship of the variables, we can take those for granted by the randomized design. Assumptions 2-4 further restrict the dependencies between the variables. Janvin et al. (2024) argues for a




FIGURE 11. Directed acyclic graph illustrating the observed data structure.

plausible structure of the observed data, depicted in Figure 11. The casual DAG satisfies Assumption 2-4 and 5.

Assumption 2 is not stated explicitly by Janvin et al. (2024), but, the same argument is used for their Assumption 4: no causal path is expected to exist from E_1 to ΔY_2 that is not through ΔY_1 (we also allow mediation through E_2). However, if there exists such a path under an intervention $\delta y_1 = 0$, Assumption 2 is violated, while Assumption 4 of Janvin et al. (2024) can still hold, even though this occurs in a contrived scenario.

Assumption 3 is equivalent to Assumption 3 of Janvin et al. (2024).

Finally, under Assumption 8, Assumption 4 is equivalent to Assumption 4 of Janvin et al. (2024).

Therefore, to test the null hypothesis, Assumption 1 and 2 slightly restrict their counterparts from Janvin et al. (2024). However, no other independencies are imposed that would not hold under the DAG proposed to represent a plausible data-generating mechanism. While all of the above discussed assumptions hold under the DAG in Figure 11, they would hold even if E_1 had a direct effect on E_2 , thus in this sense, our conditions are more general than the ones imposed by Janvin et al. (2024).

F. Hazard-ratio based waning under the null hypothesis. Suppose that, similarly to Appendix C, the variables are distributed according to the following data-generating

mechanism:

- (9) $A \sim P_A$
- (10) $T \sim \text{Categorical}\{p_{doomed}, p_{helped}, p_{harmed}, p_{immune}\}$
- (11) $E_1 \sim P_{E_1}$
- (12) $\Delta Y_1 = E_1 \times (I(T_1 = 1) + (1 - A) \times I(T = 2) + A \times I(T = 3))$
- (13) $E_2 = (1 - \Delta Y_1) \times P_{E_2}$
- (14) $\Delta Y_2 = E_2 \times (I(T_1 = 1) + (1 - A) \times I(T = 2) + A \times I(T = 3))$

For simplicity, consider $P_A \sim \text{Bernoulli}(0.5)$, and $P_{E_1} \sim \text{Bernoulli}(p_{E_1})$, $P_{E_2} \sim \text{Bernoulli}(p_{E_2})$. Since at randomization all individuals are event-free, it follows that

$$IR_1 = HR_1 \stackrel{H_0}{=} \frac{P(T \in \{11, 16\})}{P(T \in \{6, 16\})} = \frac{p_{harmed} + p_{doomed}}{p_{helped} + p_{doomed}},$$

as shown in Appendices A and B.

However, at time 2, the discrete hazard can be rewritten as

$$\begin{aligned} E[\Delta Y_2 | \Delta Y_1 = 0, A = a] &= E[\Delta Y_2 | \Delta Y_1 = 0, A = a, E_1 = 1]P(E_1 = 1 | \Delta Y_1 = 0, A = a) \\ &\quad + E[\Delta Y_2 | \Delta Y_1 = 0, A = a, E_1 = 0]P(E_1 = 0 | \Delta Y_1 = 0, A = a) \\ &\stackrel{\text{Assumption 7-9}}{=} E[\Delta Y_2^a | \Delta Y_1^a = 0, E_1^a = 1]P(E_1^a = 1 | \Delta Y_1^a = 0) \\ &\quad + E[\Delta Y_2^a | \Delta Y_1^a = 0, E_1^a = 0]P(E_1^a = 0 | \Delta Y_1^a = 0) \\ &\stackrel{\text{Assumption 1}}{=} E[\Delta Y_2^a | \Delta Y_1^a = 0, E_1^a = 1, E_2^a = 1] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 1)P(E_1^a = 1 | \Delta Y_1^a = 0) \\ &\quad + E[\Delta Y_2^a | \Delta Y_1^a = 0, E_1^a = 0, E_2^a = 1] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 0)P(E_1^a = 0 | \Delta Y_1^a = 0) \\ &\stackrel{\text{Assumption 7}}{=} E[\Delta Y_2^{a, e_1=1, e_2=1} | \Delta Y_1^{a, e_1=1} = 0, E_1^a = 1, E_2^{a, e_1=1} = 1] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 1)P(E_1^a = 1 | \Delta Y_1^a = 0) \\ &\quad + E[\Delta Y_2^{a, e_1=0, e_2=1} | \Delta Y_1^{a, e_1=0} = 0, E_1^a = 0, E_2^{a, e_1=0} = 1] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 0)P(E_1^a = 0 | \Delta Y_1^a = 0) \\ &\stackrel{\text{Assumption 4, 5}}{=} E[\Delta Y_2^{a, e_1=1, e_2=1} | \Delta Y_1^{a, e_1=1} = 0] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 1)P(E_1^a = 1 | \Delta Y_1^a = 0) \\ &\quad + E[\Delta Y_2^{a, e_1=0, e_2=1} | \Delta Y_1^{a, e_1=0} = 0] \\ &\quad \times P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 0)P(E_1^a = 0 | \Delta Y_1^a = 0). \end{aligned}$$

Under Assumption 2 and the null hypothesis,

$$E[\Delta Y_2^{a, e_1=1, e_2=1} | \Delta Y_1^{a, e_1=1} = 0] = 0.$$

The conditional probability of no exposure can be rewritten as

$$\begin{aligned}
 P(E_1^a = 0 | \Delta Y_1^a = 0) &= \frac{P(\Delta Y_1^a = 0 | E_1^a = 0)P(E_1^a = 0)}{P(\Delta Y_1^a = 0 | E_1^a = 1)P(E_1^a = 1) + P(\Delta Y_1^a = 0 | E_1^a = 0)P(E_1^a = 0)} \\
 &\stackrel{\text{Assumption 1}}{=} \frac{P(E_1^a = 0)}{P(\Delta Y_1^a = 0 | E_1^a = 1)P(E_1^a = 1) + P(E_1^a = 0)} \\
 &\stackrel{\text{Assumption 7, 4}}{=} \frac{P(E_1^a = 0)}{P(\Delta Y_1^{a,e_1=1} = 0)P(E_1^a = 1) + P(E_1^a = 0)}.
 \end{aligned}$$

Similarly, under Assumption 1

$$E[\Delta Y_2^{a,e_1=0,e_2=1} | \Delta Y_1^{a,e_1=0} = 0] = P(\Delta Y_2^{a,e_1=0,e_2=1} = 1, \Delta Y_1^{a,e_1=0} = 0) = P(\Delta Y_2^{a,e_1=0,e_2=1} = 1),$$

where we used that $\Delta Y_1 = 1 \implies \Delta Y_2 = 0$

Therefore,

$$\begin{aligned}
 E[\Delta Y_2 | \Delta Y_1 = 0, A = a] &= P(\Delta Y_2^{a,e_1=0,e_2=1} = 1)P(E_2^a = 1 | \Delta Y_1^a = 0, E_1^a = 0) \\
 &\quad \times \frac{P(E_1^a = 0)}{P(\Delta Y_1^{a,e_1=1} = 0)P(E_1^a = 1) + P(E_1^a = 0)}.
 \end{aligned}$$

Given the data-generating mechanism, in particular the fact that there is no confounding between E_1 and E_2 , we have $E_2 \perp\!\!\!\perp (A, E_1) | \Delta Y_1 = 0$. Thus

$$\begin{aligned}
 E[\Delta Y_2 | \Delta Y_1 = 0, A = a] &= P(\Delta Y_2^{a,e_1=0,e_2=1} = 1)P(E_2^a = 1 | \Delta Y_1^a = 0) \\
 &\quad \times \frac{P(E_1^a = 0)}{P(\Delta Y_1^{a,e_1=1} = 0)P(E_1^a = 1) + P(E_1^a = 0)}.
 \end{aligned}$$

Moreover, in the proposed data-generating mechanism,

$$P(E_2^{a=1} = 1 | \Delta Y_1^{a=1} = 0) = P(E_2^{a=0} = 1 | \Delta Y_1^{a=0} = 0),$$

see Equation 13. Thus, the hazard ratio at time 2, is equal to

$$HR_2 = \frac{P(\Delta Y_1^{a=1,e_1=1} = 1) P(\Delta Y_1^{a=0,e_1=1} = 0)P(E_1 = 1) + P(E_1 = 0)}{P(\Delta Y_1^{a=0,e_1=1} = 1) P(\Delta Y_1^{a=1,e_1=1} = 0)P(E_1 = 1) + P(E_1 = 0)},$$

where we used Assumption 3 to cancel out $P(E_1^a = 1)$, and the fact that under the null hypothesis $P(\Delta Y_2^{a,e_1=0,e_2=1} = 1) = P(\Delta Y_1^{a,e_1=1} = 1)$. Therefore, the hazard ratio does not only depend on the probability of the outcome given exposure, but also on the probability of the time 1 exposure. Even though the principal strata did not change over time, the time 2 hazard ratio is different from the time 1 hazard ratio by a factor of $\frac{P(\Delta Y_1^{a=0,e_1=1}=0)P(E_1=1)+P(E_1=0)}{P(\Delta Y_1^{a=1,e_1=1}=0)P(E_1=1)+P(E_1=0)}$. Thus, even if the first interval exposure increases, it is not guaranteed, that the ratio of the hazard ratios will increase or decrease monotonically, without knowledge of the distribution of the principal strata. See simulation results on testing the sharp null hypothesis of no waning (Hypothesis 1) using the equality of the hazard ratios in Appendix C of the main document.

G. Variance estimation. To construct valid statistical tests for $\frac{\widehat{IR}_1}{\widehat{IR}_2}$, the limiting distribution of its estimator must be known.

Denote with $\Delta Y_i \in \{0, 1, 2\}$ as the multivariate outcome, corresponding to the outcome of interest, not happening, happening at time 1, or time 2, respectively, and denote with $A_i \in \{0, 1\}$ the treatment assignment of individual $i \in \{1, \dots, n\}$. Then, the estimators can be defined as

$$\widehat{IR}_k := \frac{(\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = k)) / \sum_{i=1}^n I(A_i = 1)}{(\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = k)) / \sum_{i=1}^n I(A_i = 0)}$$

Using the log-normal approximation of the empirical means (Katz et al., 1978) the two incidence ratios can be approximated with

$$\log(\widehat{IR}_1) \sim \mathcal{N}(\log(IR_1), \sigma_{IR_1}^2) \quad \log(\widehat{IR}_2) \sim \mathcal{N}(\log(IR_2), \sigma_{IR_2}^2),$$

with estimated variance $\widehat{\sigma}_{IR_k}^2 = \frac{1 - \sum_{i=1}^n I(A_i=1)I(\Delta Y_i=k) / \sum_{i=1}^n I(A=1)}{\sum_{i=1}^n I(A_i=1)I(\Delta Y_i=k)} + \frac{1 - \sum_{i=1}^n I(A_i=0)I(\Delta Y_i=k) / \sum_{i=1}^n I(A=0)}{\sum_{i=1}^n I(A_i=0)I(\Delta Y_i=k)}$, based on the δ -method (was, 2006), and using the fact that the outcomes in the two arms are independent of each other (due to the assumption of no interference).

However, if we wish to derive the variance for $\widehat{IR}_1/\widehat{IR}_2$, or by the log-normal approximation, the variance of $\log(\widehat{IR}_1) - \log(\widehat{IR}_2)$, the outcomes of interest across time are no longer independent, thus the estimator

$$\begin{aligned} \widehat{\sigma}_{IR_1/IR_2}^{*2} &:= \widehat{\sigma}_{IR_1}^2 + \widehat{\sigma}_{IR_2}^2 \\ &= \frac{1 - \sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 1) / \sum_{i=1}^n I(A = 1)}{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 1)} + \frac{1 - \sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 1) / \sum_{i=1}^n I(A = 0)}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 1)} \\ &+ \frac{1 - \sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 2) / \sum_{i=1}^n I(A = 1)}{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 2)} + \frac{1 - \sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 2) / \sum_{i=1}^n I(A = 0)}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 2)} \end{aligned}$$

for the variance of the difference of the log incidence ratios is biased.

Since the correlation between the incidence ratios is unknown, which we could derive only when we have access to the distribution of the principal strata and the distribution of the exposures over the two time-points, the estimated variance of the log-difference can be upper-bounded by

$$\widehat{\sigma}_{IR_1/IR_2}^{wide2} = \widehat{\sigma}_{IR_1}^2 + \widehat{\sigma}_{IR_2}^2 + 2\sqrt{\widehat{\sigma}_{IR_1}^2}\sqrt{\widehat{\sigma}_{IR_2}^2}.$$

Alternatively, instead of applying the δ -method separately to IR_1 and IR_2 , we can directly apply it to the ratio IR_1/IR_2 .

Denote the total number no events, events at time 1, events at time 2 with $\mathbf{M}^a = (M_0^a, M_1^a, M_2^a)$ under treatment a , and the total number of individuals randomized to treatment a with N^a . Then M^a has a multinomial distribution

$$\mathbf{M}^a \sim \text{Multinomial}(N^a, (p_0^a, p_1^a, p_2^a)),$$

where p_k^a -s are determined by the distribution of the principal strata and the exposures.

The estimator of interest is

$$\widehat{IR_1/IR_2} := \frac{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 1)}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 1)} \bigg/ \frac{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 2)}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 2)}$$

Using the fact that

$$\mathbf{M}^a = \left(\sum_{i=1}^n I(A_i = a)I(\Delta Y_i = 0), \sum_{i=1}^n I(A_i = a)I(\Delta Y_i = 1), \sum_{i=1}^n I(A_i = a)I(\Delta Y_i = 2) \right)$$

and that two arms are uncorrelated, the mean and the covariance of the estimators of interest,

$$\mathbf{C} = \left(\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 1), \sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 2), \right. \\ \left. \sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 1), \sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 2) \right)^\top$$

are

$$\mu := E[\mathbf{C}] = \begin{pmatrix} N_1 p_1^1 \\ N_1 p_2^1 \\ N_0 p_1^0 \\ N_0 p_2^0 \end{pmatrix} \quad \Sigma(\mathbf{C}) = \begin{pmatrix} N_1 p_1^1(1 - p_1^1) & -N_1 p_1^1 p_2^1 & 0 & 0 \\ -N_1 p_1^1 p_2^1 & N_1 p_2^1(1 - p_2^1) & 0 & 0 \\ 0 & 0 & N_0 p_1^0(1 - p_1^0) & -N_0 p_1^0 p_2^0 \\ 0 & 0 & -N_0 p_1^0 p_2^0 & N_0 p_2^0(1 - p_2^0) \end{pmatrix}$$

Using the multivariate δ -method for some $g(U_1, U_2, U_3, U_4) = \log(U_1) - \log(U_2) - \log(U_3) + \log(U_4)$ with the gradient $\nabla g(\mathbf{U}) = \left(\frac{1}{U_1}, -\frac{1}{U_2}, -\frac{1}{U_3}, \frac{1}{U_4} \right)^\top$, we have that the variance of $g(\mathbf{C})$ is equal to

$$\text{Var}(g(\mathbf{C})) = \nabla g(\mathbf{U})^\top \big|_{\mathbf{U}=\mu} \Sigma(\mathbf{C}) \nabla g(\mathbf{U}) \big|_{\mathbf{U}=\mu} = \frac{1}{N_1 p_1^1} + \frac{1}{N_1 p_2^1} + \frac{1}{N_0 p_1^0} + \frac{1}{N_0 p_2^0},$$

which we can estimate by

$$\widehat{\text{Var}(g(\mathbf{C}))} = \frac{1}{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 1)} + \frac{1}{\sum_{i=1}^n I(A_i = 1)I(\Delta Y_i = 2)} \\ + \frac{1}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 1)} + \frac{1}{\sum_{i=1}^n I(A_i = 0)I(\Delta Y_i = 2)}$$

The derivation of the variance shows that using incidence ratios instead of hazard ratios not only has the benefit of stability when the null hypothesis holds, but also has statistical advantages. Since the hazard ratio is calculated across different populations over time, the two arms cannot be modeled as two multinomial distributions. Their correlation is not known, as it depends on the principal strata and the exposure of individuals; therefore, to derive valid statistical tests, we have to rely on non-parametric bootstrap. Thus, having patient-level data is necessary to assess the equality of hazard ratios over time, while for the incidence ratios, summary data is sufficient.

When we only have access to summary data, such as the analysis of the BNT162b2 vaccine against COVID-19, we follow the Estimation procedure discussed by Janvin et al. (2024) in their Appendix.

H. Conditional waning. The challenge effect, and thus waning, can be defined conditional on baseline covariates.

Definition 2 (Conditional challenge effect). Denote the measured baseline covariates $\mathbf{L} \in \mathcal{L}$. Then the conditional challenge effects at times 1 and 2 are

$$\begin{aligned} VE_1^{\text{challenge}}(\mathbf{l}) &= 1 - \frac{E[\Delta Y_1^{a=1, e_1=1} | \mathbf{L} = \mathbf{l}]}{E[\Delta Y_1^{a=0, e_1=1} | \mathbf{L} = \mathbf{l}]}, \\ VE_2^{\text{challenge}}(\mathbf{l}) &= 1 - \frac{E[\Delta Y_1^{a=1, e_1=0, e_2=1} | \mathbf{L} = \mathbf{l}]}{E[\Delta Y_1^{a=0, e_1=0, e_2=1} | \mathbf{L} = \mathbf{l}]} \end{aligned}$$

Correspondingly, the incidence rates are

$$IR_1(\mathbf{l}) := \frac{E[\Delta Y_1 | A = 1, \mathbf{L} = \mathbf{l}]}{E[\Delta Y_1 | A = 0, \mathbf{L} = \mathbf{l}]} \quad IR_2(\mathbf{l}) := \frac{E[\Delta Y_2 | A = 1, \mathbf{L} = \mathbf{l}]}{E[\Delta Y_2 | A = 0, \mathbf{L} = \mathbf{l}]}$$

Suppose that Assumption 3 holds only conditionally on the baseline covariates.

Assumption 10 (Conditional exposure exchangeability).

$$\begin{aligned} E_1^a &\perp\!\!\!\perp \Delta Y_2^{a, e_1=0} | E_2^{a, e_1=0}, \mathbf{L}, & E_1^a &\perp\!\!\!\perp \Delta Y_1^{a, e_1} | \mathbf{L}, \\ E_2^{a, e_1=0} &\perp\!\!\!\perp \Delta Y_2^{a, e_1=0, e_2} | \mathbf{L}. \end{aligned}$$

For example, suppose that there are some *measured* confounders between the exposures and the outcome, such as age or physical fitness. Then, in order for the independence to hold between the outcomes and the exposures, all confounders should be conditioned on.

Similarly, if randomization occurs conditional on the baseline covariates, Assumption 8 and 9 hold conditionally.

Assumption 11 (Conditional treatment exchangeability).

$$E_1^a, \Delta Y_1^a, \Delta Y_1^{a, e_1}, E_2^{a, e_1}, E_2^{a, e_1 \delta y_1=0}, \Delta Y_2^{a, e_1, \delta y_1=0, e_2} \perp\!\!\!\perp A | \mathbf{L}$$

for all $a, e_1, e_2 \in \{0, 1\}$.

Assumption 12 (Conditional positivity).

$$P(A = a | \mathbf{L} = \mathbf{l}) > 0$$

for all $a \in \{0, 1\}$, and for all $\mathbf{l} \in \mathcal{L}$, such that $P(\mathbf{L} = \mathbf{l}) > 0$.

Analogously to the proof in Appendix B we can show that under Hypothesis 1 and Assumptions 1-3 and 10

$$IR_1(\mathbf{l}) = IR_2(\mathbf{l}) \quad \forall \mathbf{l} \in \mathcal{L}$$

Then, the null hypothesis of no waning may be evaluated separately across subgroups; however, the analyses should control for multiple testing (Simes, 1986; Benjamini and Hochberg, 1995).

Alternatively, assume constant proportionality across the subgroups defined by \mathbf{L} .

Assumption 13 (Constant incidence ratios).

$$\begin{aligned} E[\Delta Y_1 | A = 1, \mathbf{L} = \mathbf{l}] &= \alpha_1 E[\Delta Y_1 | A = 0, \mathbf{L} = \mathbf{l}] \\ E[\Delta Y_2 | A = 1, \mathbf{L} = \mathbf{l}] &= \alpha_2 E[\Delta Y_2 | A = 0, \mathbf{L} = \mathbf{l}] \end{aligned}$$

for all $\mathbf{l} \in \mathcal{L}$.

Under the null hypothesis and Assumptions 1 and 10, we have that $IR_1(\mathbf{l}) = IR_2(\mathbf{l})$. Thus, it follows that in this setting $\alpha_1 = \alpha_2$ must hold. Then

$$\frac{IR_1}{IR_2} = \frac{\int IR_1(\mathbf{l}) dP(\mathbf{L})}{\int IR_2(\mathbf{l}) dP(\mathbf{L})} = \int \frac{IR_1(\mathbf{l})}{IR_2(\mathbf{l})} dP(\mathbf{L}) = \frac{\alpha_1}{\alpha_2} \int \frac{1}{1} dP(\mathbf{L}) = 1,$$

therefore, the null hypothesis implies that there is no marginal population-level waning.